PAVmed subsidiary Lucid Diagnostics raises $5M via Series A-1 Convertible Preferred Stock

PAVmed Inc.

Lucid Diagnostics, majority-owned PAVmed sub, sold 5,000 shares of newly designated Series A-1 Convertible Preferred at $1,000/share.
Gross proceeds of $5.0 million from accredited investors; private placement closed October 18, 2023.
Certificate of Designation and Registration Rights Agreement filed by Lucid on Form 8-K; terms incorporated by reference.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

PAVmed Inc. entered into Subscription Agreement with certain accredited investors valued at aggregate gross proceeds to Lucid of $5.0 million (effective 2023-10-17).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: aggregate gross proceeds to Lucid of $5.0 million
Effective: 2023-10-17

Exact text from the filing

Effective as of October 17, 2023, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accredited investors for the sale of 5,000 shares of newly designated Series A-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series A-1 Preferred Stock ”), at a purchase price of $1,000 per share, for aggregate gross proceeds to Lucid of $5.0 million

View on SEC.gov

Browse all material agreements →

PAVmed Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-037575

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.